Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Molecular Profile | HRAS G12V |
| Therapy | Daraxonrasib |
| Indication/Tumor Type | lung non-small cell carcinoma |
| Response Type | predicted - sensitive |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|---|---|---|---|---|---|---|
| HRAS G12V | lung non-small cell carcinoma | predicted - sensitive | Daraxonrasib | Case Reports/Case Series | Actionable | In a Phase I/II trial, Rasonque (daraxonrasib) demonstrated safety and resulted in objective response rates (ORR) of 31% (8/26), 34% (20/59), and 37% (19/51) at dosages of 120mg or less, 160 to 220mg, or 300mg, respectively, in previously treated non-small cell lung cancer patients with RAS G12, G13, or Q61 mutations, with a 42% (14/33) ORR at 160 to 220mg and 43% (12/28) ORR at 300mg in patients with RAS G12 mutations, including HRAS G12V, who did not receive prior docetaxel (PMID: 42685317; NCT05379985). | 42685317 |
| PubMed Id | Reference Title | Details |
|---|---|---|
| (42685317) | Daraxonrasib for Previously Treated RAS-Mutant Non-Small-Cell Lung Cancer. | Full reference... |